Antiviral Strategies Against Human Respiratory Viruses

A special issue of Pathogens (ISSN 2076-0817). This special issue belongs to the section "Viral Pathogens".

Deadline for manuscript submissions: 10 November 2025 | Viewed by 1728

Special Issue Editors


E-Mail Website
Guest Editor
Department of Molecular Medicine, University of Padova, 35121 Padova, Italy
Interests: emerging viruses; virus-host interaction; antiviral discovery
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Molecular Medicine, University of Padua, Via A. Gabelli 63, 35121 Padua, Italy
Interests: small-molecule inhibitors; protein–protein interaction inhibitors; antiviral discovery; emerging viruses
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Respiratory viruses continue to pose a significant threat to public health due to their rapid spread, often leading to epidemics or pandemics, as recently witnessed with the SARS-CoV-2 pandemic. Despite the availability of prophylactic and therapeutic measures, further research is required to effectively counteract respiratory infections.

This Special Issue of Pathogens aims to collect and summarize current antiviral strategies against respiratory viruses, including novel vaccine development platforms, host immune modulators, drug repurposing strategies, small-molecule inhibitors, and innovative technologies employed in drug design.

Invited authors are encouraged to submit their latest findings and results in the form of research papers or reviews. Submitted data may encompass in vitro, in vivo, or translational studies.

Researchers are encouraged to extend this invitation to colleagues and others interested in contributing to this important topic.

Dr. Cristiano Salata
Dr. Chiara Bertagnin
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pathogens is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • respiratory viruses
  • antiviral molecules
  • vaccines
  • immunomodulation
  • immunotherapeutics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

20 pages, 387 KiB  
Review
Digestive Manifestations of Post-COVID-19: A Focus on Therapeutic Strategies
by Cristina Stasi and Massimo Bellini
Pathogens 2025, 14(6), 555; https://doi.org/10.3390/pathogens14060555 - 3 Jun 2025
Viewed by 1418
Abstract
Post-COVID-19 is a chronic infection-related syndrome, including exacerbations of pre-existing or newly diagnosed conditions that have been established after the acute phase of COVID-19 and have demonstrated a wide range of systemic effects beyond the lungs. SARS-CoV-2 attaches to its receptor, angiotensin-converting enzyme [...] Read more.
Post-COVID-19 is a chronic infection-related syndrome, including exacerbations of pre-existing or newly diagnosed conditions that have been established after the acute phase of COVID-19 and have demonstrated a wide range of systemic effects beyond the lungs. SARS-CoV-2 attaches to its receptor, angiotensin-converting enzyme 2 (ACE-2). Transmembrane serine protease 2 (TMPRSS2) facilitates viral entry and spread. ACE-2 receptors are detectable in several tissues, including the respiratory mucosa, digestive tract, heart, kidney, and brain. Several investigations have demonstrated an increase in digestive manifestations post-acute COVID-19, likely related to an alteration in the intestinal microbiota following infection. These changes can lead to a loss of species diversity, resulting in an overgrowth of opportunistic pathogens and deprivation of commensal bacteria. In this context, post-infection irritable bowel syndrome shows an increased incidence compared to controls. Growing evidence also suggests the enduring presence of SARS-CoV-2 in the gut tissue. Studies are ongoing to investigate antiviral agents that counteract prolonged COVID-19 symptoms. Therefore, the objectives of this review were to summarize the digestive manifestations, focusing on irritable bowel syndrome and therapeutic strategies. This review gives an overview of studies published in English in the last two years on the PubMed database. Full article
(This article belongs to the Special Issue Antiviral Strategies Against Human Respiratory Viruses)
Show Figures

Figure 1

Back to TopTop